康哲藥業(00867.HK)夥泰諾麥博開發全人源抗新冠病毒抗體新藥
康哲藥業(00867.HK)宣佈,與泰諾麥博生物技術簽訂合作協議,就全人源抗新冠病毒抗體新藥等兩款創新產品達成合作。於今年4月康哲藥業對泰諾麥博進行股權投資,並持續導入創新產品,目前雙方共就4款創新產品達成合作。
根據合作協議,集團將與泰諾麥博成立新合營公司,並將以現金出資,而泰諾麥博以兩款合作產品相關技術的全球權益作爲無形資產出資,雙方將分別持有合營公司50%的權益,由集團將負責產品後續的臨牀開發及在大中華地區的商業化工作,並擁有在大中華地區外同等條件下的優先合作權。
兩款創新產品均基於泰諾麥博專有技術平臺HitmAb開發,雙方將充分發揮自身優勢,加速推動創新藥從發現、臨牀前研究、臨牀開發到商業化全進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.